Molecular Partners (MOLN) Competitors

Arvinas (NASDAQ:ARVN) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability, institutional ownership and community ranking.

Does the media favor ARVN or MOLN?

In the previous week, Arvinas had 5 more articles in the media than Molecular Partners. MarketBeat recorded 10 mentions for Arvinas and 5 mentions for Molecular Partners. Arvinas' average media sentiment score of 0.71 beat Molecular Partners' score of 0.31 indicating that Arvinas is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor ARVN or MOLN?

Arvinas received 184 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 66.55% of users gave Arvinas an outperform vote while only 48.15% of users gave Molecular Partners an outperform vote.

Company	Underperform	Outperform
Arvinas	Outperform Votes 197 66.55%	Underperform Votes 99 33.45%
Molecular Partners	Outperform Votes 13 48.15%	Underperform Votes 14 51.85%

Do analysts rate ARVN or MOLN?

Arvinas presently has a consensus price target of $34.33, indicating a potential upside of 256.90%. Molecular Partners has a consensus price target of $12.00, indicating a potential upside of 207.69%. Given Arvinas' higher probable upside, equities analysts plainly believe Arvinas is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.69
Molecular Partners	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Do institutionals and insiders believe in ARVN or MOLN?

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 26.5% of Molecular Partners shares are owned by institutional investors. 5.2% of Arvinas shares are owned by insiders. Comparatively, 5.9% of Molecular Partners shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Which has more risk and volatility, ARVN or MOLN?

Arvinas has a beta of 2.3, suggesting that its share price is 130% more volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.

Is ARVN or MOLN more profitable?

Arvinas has a net margin of -75.51% compared to Molecular Partners' net margin of -1,043.01%. Arvinas' return on equity of -33.75% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-75.51%	-33.75%	-16.75%
Molecular Partners	-1,043.01%	-39.31%	-35.46%

Which has better earnings & valuation, ARVN or MOLN?

Molecular Partners has lower revenue, but higher earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$263.40M	2.51	-$198.90M	-$2.77	-3.47
Molecular Partners	$4.97M	31.68	-$69.04M	-$1.81	-2.15

Summary

Arvinas beats Molecular Partners on 12 of the 19 factors compared between the two stocks.